Article
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.
Leukemia - 1 Oct 2022
Allert Catana, Waclawiczek Alexander, Zimmermann Sarah Miriam Naomi, Göllner Stefanie, Heid Daniel, Janssen Maike, Renders Simon, Rohde Christian, Bauer Marcus, Bruckmann Margarita, Zinz Rafael, Pauli Cornelius, Besenbeck Birgit, Wickenhauser Claudia, Trumpp Andreas, Krijgsveld Jeroen, Müller-Tidow Carsten, Blank Maximilian Felix
Abstract excerpt
FLT3 tyrosine kinase inhibitor (TKI) therapy evolved into a standard therapy in FLT3-mutated AML. TKI resistance, however, develops frequently with poor outcomes. We analyzed acquired TKI resistance in AML cell lines by multilayered proteome analyses. Leupaxin (LPXN), a regulator of cell migration and adhesion, was induced during early resistance development, alongside the tyrosine kinase PTK2B which...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.